ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
p300-Mediated H3K18 Lactylation Drives Radiation-Induced Pulmonary Fibrosis via VIRMA-Dependent m6A Modification of GATA3.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Radiation-induced pulmonary fibrosis, a devastating thoracic radiotherapy sequela, features aberrant ECM deposition and irreversible loss of functional lung architecture. However, the exact molecular mechanisms governing AECII dysfunction and fate transition during RIPF remain poorly understood. Here, we identify a novel metabolic-epigenetic-epitranscriptomic cascade that orchestrates the pro-fibrotic fate of AECIIs. We demonstrate that radiation exposure triggers a glycolytic shift in AECIIs, resulting in pathological intracellular lactate accumulation. This metabolic stress is directly coupled to chromatin remodeling via p300-mediated H3K18la at the VIRMA promoter, driving its robust transcriptional activation. Consequently, elevated VIRMA promotes a pro-fibrotic epitranscriptomic landscape by increasing m6A enrichment on the GATA3 mRNA. Recognition of this modification by the m6A reader YTHDF1 extends GATA3 mRNA half-life. The ensuing GATA3 accumulation initiates EMT and exacerbates ECM deposition. Strikingly, utilizing AECII-specific Virma conditional knockout mice, we confirmed the essential role of this axis in vivo; genetic ablation of Virma preserved alveolar integrity and conferred resistance to radiation-induced fibrogenesis. Furthermore, pharmacological inhibition of the H3K18la writer p300 using C646 abrogated the fibrotic phenotype. Collectively, our findings elucidate how radiation-induced metabolic reprogramming is durably inscribed into the epigenome to dictate cell fate, offering a therapeutic rationale for targeting the H3K18la/VIRMA/GATA3 axis in RIPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.